Phase 1 Myeloma Trial, Recruiting NCT06375044 Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. Condition: Myeloma
Back to Myeloma

Phase 1 Myeloma Trial, Recruiting

NCT06375044
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have signed a consent form agreeing to participate.
  • You are 18 years of age or older.
  • You have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, and all standard treatment options have already been tried.
  • Doctors expect you to live for at least 12 weeks.
  • You are generally able to carry out daily activities with little or no limitation (confirm with trial site regarding how this is measured).
  • Your blood, liver, and kidney functions are at acceptable levels.

Who may not be able to join:

  • You still have significant side effects from previous cancer treatments that have not cleared up (minor hair loss or mild nerve-related symptoms may be acceptable).
  • You have an active hepatitis B or hepatitis C infection at certain levels (some people with hepatitis B may still be eligible if they receive antiviral treatment — confirm with trial site).
  • You have HIV or AIDS.
  • You are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period.
  • You have an active autoimmune disease, though some milder conditions such as vitiligo, well-controlled thyroid issues, mild psoriasis, or insulin-controlled type 1 diabetes may still be acceptable (confirm with trial site).
  • You have had another type of cancer in the past 3 years, unless it was certain types of skin cancer, early-stage bladder cancer, or very early non-spreading cancers of the prostate, cervix, or breast.
  • Your multiple myeloma has spread to the brain or spinal fluid, or you are showing signs of this.
  • You have had an active infection within the 14 days before starting the trial treatment.

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 8573330740

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
24 May 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China 🇺🇸 United States

Primary endpoints

Dose-limiting toxicity (DLT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov